Oropharynx squamous cell carcinoma
diseaseOn this page
Also known as epidermoid carcinoma of oropharynxepidermoid carcinoma of the oropharynxoropharyngeal epidermoid carcinomaoropharyngeal squamous cell carcinomaoropharyngeal throat squamous cell cancersquamous cell carcinoma of oropharynx
Summary
Oropharynx squamous cell carcinoma (MONDO:0044704) is a cancer and 143 clinical trials. Top therapeutic interventions include cisplatin, cetuximab, and cabozantinib. A subtype of pharyngeal squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Clinical trials: 143
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 100 000 | 3.12 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | oropharynx squamous cell carcinoma |
| Mondo ID | MONDO:0044704 |
| Orphanet | 500478 |
| DOID | DOID:0070664 |
| ICD-11 | 839740136 |
| NCIT | C8181 |
| UMLS | C0280313 |
| MedGen | 76094 |
| GARD | 0017928 |
| Anatomy (UBERON) | UBERON:0001729 |
| Is cancer (heuristic) | yes |
Also known as: epidermoid carcinoma of oropharynx · epidermoid carcinoma of the oropharynx · oropharyngeal epidermoid carcinoma · oropharyngeal squamous cell carcinoma · oropharyngeal throat squamous cell cancer · squamous cell carcinoma of oropharynx
Data availability: 28 cell lines.
Disease family
This is a subtype of pharyngeal squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › respiratory system cancer › pharynx cancer › pharyngeal squamous cell carcinoma › oropharynx squamous cell carcinoma
Related subtypes (1): hypopharynx squamous cell carcinoma
Subtypes (1): tonsillar squamous cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 143.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 57 |
| Not specified | 45 |
| PHASE1 | 21 |
| PHASE3 | 8 |
| PHASE2/PHASE3 | 5 |
| EARLY_PHASE1 | 5 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00588770 | PHASE3 | ACTIVE_NOT_RECRUITING | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT01810913 | PHASE2/PHASE3 | RECRUITING | Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer |
| NCT01893307 | PHASE3 | ACTIVE_NOT_RECRUITING | Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer |
| NCT03952585 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer |
| NCT05333523 | PHASE3 | RECRUITING | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. |
| NCT05721755 | PHASE3 | ACTIVE_NOT_RECRUITING | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT06589804 | PHASE3 | RECRUITING | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment |
| NCT01439724 | PHASE3 | COMPLETED | Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients |
| NCT01874171 | PHASE3 | UNKNOWN | Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC |
| NCT02236936 | PHASE3 | TERMINATED | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck |
| NCT03258554 | PHASE2/PHASE3 | COMPLETED | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin |
| NCT05050162 | PHASE2/PHASE3 | SUSPENDED | Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer |
| NCT06513884 | PHASE2/PHASE3 | WITHDRAWN | A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer |
| NCT00494182 | PHASE2 | ACTIVE_NOT_RECRUITING | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
| NCT03410615 | PHASE2 | ACTIVE_NOT_RECRUITING | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC |
| NCT03468218 | PHASE2 | ACTIVE_NOT_RECRUITING | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer |
| NCT04220749 | PHASE2 | RECRUITING | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma |
| NCT04609280 | PHASE2 | ACTIVE_NOT_RECRUITING | Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) |
| NCT04671667 | PHASE2 | RECRUITING | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma |
| NCT04718415 | PHASE2 | ACTIVE_NOT_RECRUITING | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma |
| NCT04852328 | PHASE2 | RECRUITING | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma |
| NCT04858269 | PHASE2 | ACTIVE_NOT_RECRUITING | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients |
| NCT04862650 | PHASE2 | ACTIVE_NOT_RECRUITING | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
| NCT05098119 | PHASE2 | RECRUITING | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) |
| NCT05136196 | PHASE2 | RECRUITING | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study |
| NCT05172258 | PHASE2 | ACTIVE_NOT_RECRUITING | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck |
| NCT05268614 | PHASE2 | RECRUITING | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma |
| NCT05582122 | PHASE2 | RECRUITING | SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers |
| NCT05996523 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer |
| NCT06009861 | PHASE2 | ACTIVE_NOT_RECRUITING | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) |
| NCT06088381 | PHASE2 | RECRUITING | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) |
| NCT06323460 | PHASE2 | RECRUITING | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer |
| NCT06532279 | PHASE2 | RECRUITING | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer |
| NCT06636734 | PHASE2 | RECRUITING | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial |
| NCT06728618 | PHASE2 | NOT_YET_RECRUITING | Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma |
| NCT06759155 | PHASE2 | NOT_YET_RECRUITING | Phase II Clinical Trial of De-Intensified Therapy in Human Papilloma Virus (HPV) Associated Oropharyngeal Squamous Cell Carcinoma |
| NCT06861712 | PHASE2 | NOT_YET_RECRUITING | Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer |
| NCT06980038 | PHASE2 | RECRUITING | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer |
| NCT07044635 | PHASE2 | RECRUITING | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma. |
| NCT07058805 | PHASE2 | RECRUITING | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 27 |
| CETUXIMAB | 4 | 5 |
| CABOZANTINIB | 4 | 2 |
| CEMIPLIMAB | 4 | 2 |
| ALPELISIB | 4 | 1 |
| ATEZOLIZUMAB | 4 | 1 |
| DURVALUMAB | 4 | 1 |
| FLUDEOXYGLUCOSE F 18 | 4 | 1 |
| INFIGRATINIB | 4 | 1 |
| LOVASTATIN | 4 | 1 |
| NIVOLUMAB | 4 | 1 |
| PORFIMER SODIUM | 4 | 1 |
| SODIUM THIOSULFATE | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| TREMELIMUMAB | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| IPATASERTIB | 3 | 2 |
| CEDIRANIB MALEATE | 3 | 1 |
| FICLATUZUMAB | 3 | 1 |
| XEVINAPANT | 3 | 1 |
| ETIMUPEPIMUT | 2 | 1 |
| IMSAPEPIMUT | 2 | 1 |
| SOY ISOFLAVONES | 2 | 1 |
| VIDUTOLIMOD | 2 | 1 |
| HB-202 | 1 | 1 |
| NINSIPAPOGENE SIBARNAREPVEC | 1 | 1 |
| CHEMBL5412235 | 0 | 1 |
| CHEMBL4215501 | 0 | 1 |
| CHEMBL4849721 | 0 | 1 |
| CHEMBL3753202 | 0 | 1 |